Nanoviricides Stock Z Score
NNVC Stock | USD 1.15 0.01 0.88% |
NanoViricides | Z Score |
NanoViricides Company Z Score Analysis
NanoViricides' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
NanoViricides Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for NanoViricides is extremely important. It helps to project a fair market value of NanoViricides Stock properly, considering its historical fundamentals such as Z Score. Since NanoViricides' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NanoViricides' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NanoViricides' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
Based on the company's disclosures, NanoViricides has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
NanoViricides Current Valuation Drivers
We derive many important indicators used in calculating different scores of NanoViricides from analyzing NanoViricides' financial statements. These drivers represent accounts that assess NanoViricides' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NanoViricides' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 42.0M | 50.6M | 21.7M | 13.4M | 15.4M | 14.6M | |
Enterprise Value | 29.4M | 30.2M | 7.7M | 5.2M | 6.0M | 5.7M |
NanoViricides Fundamentals
Return On Equity | -0.58 | ||||
Return On Asset | -0.36 | ||||
Current Valuation | 8.18 M | ||||
Shares Outstanding | 11.78 M | ||||
Shares Owned By Insiders | 4.61 % | ||||
Shares Owned By Institutions | 10.29 % | ||||
Number Of Shares Shorted | 98.92 K | ||||
Price To Earning | (6.02) X | ||||
Price To Book | 1.18 X | ||||
EBITDA | (7.84 M) | ||||
Net Income | (8.59 M) | ||||
Cash And Equivalents | 14.07 M | ||||
Cash Per Share | 1.21 X | ||||
Total Debt | 94.79 K | ||||
Debt To Equity | 0 % | ||||
Current Ratio | 34.92 X | ||||
Book Value Per Share | 1.06 X | ||||
Cash Flow From Operations | (5.67 M) | ||||
Short Ratio | 3.94 X | ||||
Earnings Per Share | (0.80) X | ||||
Target Price | 6.5 | ||||
Beta | 0.71 | ||||
Market Capitalization | 13.43 M | ||||
Total Asset | 16.9 M | ||||
Retained Earnings | (131.08 M) | ||||
Working Capital | 7.91 M | ||||
Current Asset | 24.38 M | ||||
Current Liabilities | 6.74 M | ||||
Net Asset | 16.9 M |
About NanoViricides Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NanoViricides's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NanoViricides using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NanoViricides based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out NanoViricides Piotroski F Score and NanoViricides Valuation analysis. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for NanoViricides Stock analysis
When running NanoViricides' price analysis, check to measure NanoViricides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NanoViricides is operating at the current time. Most of NanoViricides' value examination focuses on studying past and present price action to predict the probability of NanoViricides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NanoViricides' price. Additionally, you may evaluate how the addition of NanoViricides to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is NanoViricides' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NanoViricides. If investors know NanoViricides will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NanoViricides listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Return On Assets (0.36) | Return On Equity (0.58) |
The market value of NanoViricides is measured differently than its book value, which is the value of NanoViricides that is recorded on the company's balance sheet. Investors also form their own opinion of NanoViricides' value that differs from its market value or its book value, called intrinsic value, which is NanoViricides' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NanoViricides' market value can be influenced by many factors that don't directly affect NanoViricides' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NanoViricides' value and its price as these two are different measures arrived at by different means. Investors typically determine if NanoViricides is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NanoViricides' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.